DLinDMA | CAS#871258-12-7

MedKoo Cat#: 555352 | Name: DLinDMA

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

DLinDMA is a cationic lipid for siRNA delivery.

Chemical Structure

DLinDMA

CAS#871258-12-7

Theoretical Analysis

MedKoo Cat#: 555352

Name: DLinDMA

CAS#: 871258-12-7

Chemical Formula: C41H77NO2

Exact Mass: 615.5954

Molecular Weight: 616.07

Elemental Analysis: C, 79.93; H, 12.60; N, 2.27; O, 5.19

Price and Availability

Size	Price	Availability
10mg	USD 90.00	Ready to ship
25mg	USD 150.00	Ready to ship
50mg	USD 225.00	Ready to ship
100mg	USD 350.00	Ready to ship
200mg	USD 600.00	Ready to ship
500mg	USD 1,250.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

DLinDMA; D-LinDMA; D-Lin-DMA;

IUPAC/Chemical Name

N,N-Dimethyl-2,3-bis[(9Z,12Z)-octadeca-9,12-dienyloxy]propan-1-amine

InChi Key

NFQBIAXADRDUGK-KWXKLSQISA-N

InChi Code

InChI=1S/C41H77NO2/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-43-40-41(39-42(3)4)44-38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2/h13-16,19-22,41H,5-12,17-18,23-40H2,1-4H3/b15-13-,16-14-,21-19-,22-20-

SMILES Code

CCCCC/C=C\C/C=C\CCCCCCCCOCC(OCCCCCCCC/C=C\C/C=C\CCCCC)CN(C)C

Appearance

Colorless to light yellow liquid

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#A9T11K08

QC Data

View QC data: current batch, Lot#A9T11K08

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

DLinDMA is a cationic lipid.

In vitro activity:

Primary bone marrow MΦ (bmMΦ) and bone marrow dendritic cells (bmDCs) were isolated and incubated with 1 and 5 µg siRNA/ml scrambled or GAPDH-specific siRNA in LNP containing DLinDAP, DLinDMA, DLinKMA, and DLinKC2-DMA for 72 hours. Following treatment, GAPDH and control α-Tubulin expression was assessed using western blot analysis and flow cytometry. In bmMΦ treated with 1 µg/ml LNP siRNA, significant GAPDH silencing (>60%) was only observed for LNP (Lipid nanoparticles) containing DLinKC2-DMA. (Figure 1a). At dose levels of 5 µg/ml, LNPs containing DLinKC2-DMA were the most potent gene silencing agents (80%). At this dose level, LNPs containing DLinDMA and DLinK-DMA also produced significant silencing (~60%), and DLinDAP was ineffective. these data indicate that LNPs containing DLinKC2-DMA were the most efficient formulation for producing significant siRNA-mediated GAPDH gene knockdown in vitro at concentrations as low as 1 µg/ml. Reference: Mol Ther. 2011 Dec;19(12):2186-200. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242662/

In vivo activity:

To test functional properties of LNP-treated APC (antigen-presenting cells), the ability of in vivo-transfected DCs to activate T cells following antigen uptake was evaluated. For this, spleen DCs (dendritic cells) of mice injected with siRNA-DLinKC2-DMA were isolated, fed with ovalbumine, and their ability to activate the T-cell line B3Z35 was assessed and compared with the untreated DCs. Flow cytometry analysis revealed that there was no difference between control and in vivo-transfected DCs in their ability to activate T cells following cross-presentation of ovalbumine antigen (Supplementary Figure S6a). The data indicates that there is essentially no functional impairment of DCs following their in vivo transfection with DLinKC2-DMA-formulated siRNA. Reference: Mol Ther. 2011 Dec;19(12):2186-200. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242662/

	Solvent	mg/mL	mM
Solubility
	DMSO	100.0	162.32
	Ethanol	3.0	4.87

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 616.07 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Basha G, Novobrantseva TI, Rosin N, Tam YY, Hafez IM, Wong MK, Sugo T, Ruda VM, Qin J, Klebanov B, Ciufolini M, Akinc A, Tam YK, Hope MJ, Cullis PR. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol Ther. 2011 Dec;19(12):2186-200. doi: 10.1038/mt.2011.190. Epub 2011 Oct 4. PMID: 21971424; PMCID: PMC3242662.

In vitro protocol:

In vivo protocol:

1: Tiffany M, Szoka FC. Co-localization of fluorescent labeled lipid nanoparticles with specifically tagged subcellular compartments by single particle tracking at low nanoparticle to cell ratios. J Drug Target. 2016 Nov;24(9):857-864. Epub 2016 Sep 30. PubMed PMID: 27600702. 2: Lin PJ, Tam YY, Hafez I, Sandhu A, Chen S, Ciufolini MA, Nabi IR, Cullis PR. Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA. Nanomedicine. 2013 Feb;9(2):233-46. doi: 10.1016/j.nano.2012.05.019. Epub 2012 Jun 12. PubMed PMID: 22698807. 3: Basha G, Novobrantseva TI, Rosin N, Tam YY, Hafez IM, Wong MK, Sugo T, Ruda VM, Qin J, Klebanov B, Ciufolini M, Akinc A, Tam YK, Hope MJ, Cullis PR. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol Ther. 2011 Dec;19(12):2186-200. doi: 10.1038/mt.2011.190. Epub 2011 Oct 4. PubMed PMID: 21971424; PubMed Central PMCID: PMC3242662. 4: Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, Sah DW, Stebbing D, Crosley EJ, Yaworski E, Hafez IM, Dorkin JR, Qin J, Lam K, Rajeev KG, Wong KF, Jeffs LB, Nechev L, Eisenhardt ML, Jayaraman M, Kazem M, Maier MA, Srinivasulu M, Weinstein MJ, Chen Q, Alvarez R, Barros SA, De S, Klimuk SK, Borland T, Kosovrasti V, Cantley WL, Tam YK, Manoharan M, Ciufolini MA, Tracy MA, de Fougerolles A, MacLachlan I, Cullis PR, Madden TD, Hope MJ. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010 Feb;28(2):172-6. doi: 10.1038/nbt.1602. Epub 2010 Jan 17. PubMed PMID: 20081866. 5: Heyes J, Palmer L, Bremner K, MacLachlan I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Release. 2005 Oct 3;107(2):276-87. PubMed PMID: 16054724.